Furthermore, patients across different response groups showed both intra- and inter-tumoral heterogeneity in their pre-treatment tumor samples, emphasizing the need for a more comprehensive investigation of the heterogeneous responses of malignant and immune cell components to NAT. This evidence concerns the gene BRD2 and neoplasm.